Information Disclosure Issues Challenge FDA Transparency Task Force
This article was originally published in The Tan Sheet
Executive Summary
FDA questions whether to disclose information on product applications that a company abandons before approval or in some cases on applications in which review is still pending
You may also be interested in...
FDA Launches System To Track Performances of Its Offices
For those wondering how many adverse events reports FDA received last month, the number of Risk Evaluation and Mitigation Strategies it cleared or the number of first generics it approved, the answers are now readily accessible
FDA Launches System To Track Performances of Its Offices
For those wondering how many adverse events reports FDA received last month, the number of Risk Evaluation and Mitigation Strategies it cleared or the number of first generics it approved, the answers are now readily accessible
FDA Launches System To Track Performances of Its Offices
For those wondering how many adverse events reports FDA received last month, the number of Risk Evaluation and Mitigation Strategies it cleared or the number of first generics it approved, the answers are now readily accessible